ArticleDiabetes, obesity & metabolism2026
Effects of 6-OHDA-Mediated Chemical Denervation of Sympathetic Axons in Inguinal Subcutaneous White Adipose Tissue.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of 6-OHDA-Mediated Chemical Denervation of Sympathetic Axons in Inguinal Subcutaneous White Adipose Tissue.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
aimsWhite adipose tissue (WAT) innervation by sensory and sympathetic axons contributes to tissue functions, but the consequences of selectively disrupting sympathetic input to WAT remain incompletely defined. MATERIALS AND
methodsWe utilised 6-hydroxydopamine (6-OHDA) as a validated approach to achieve bilateral sympathetic denervation of mouse inguinal subcutaneous WAT (ing-scWAT) and investigated impacts on adipose and whole-body metabolism.
resultsSympathetic denervation did not impact body weight or adipose mass by 16 days post-denervation but significantly altered energy expenditure. Sympathetic denervation increased both sensory neuropeptide levels and sensory innervation at 7 days, which may explain the minimal whole-body impacts, since sensory nerves can contribute to many of the same metabolic processes as sympathetic nerves in adipose. In acute studies, intra-ing-scWAT norepinephrine delivery increased calcitonin gene related peptide (CGRP) levels in the depot, while CGRP administration reduced norepinephrine levels, underscoring previous reports of nerve cross talk at the tissue level. Multi-omics profiling of sympathetically denervated ing-scWAT revealed selective remodelling of lipid signalling pathways, including accumulation of polyunsaturated fatty acid-derived oxylipins from the cytochrome P450 pathway, alongside perturbations in tricarboxylic acid cycle metabolism. These changes were distinct from CL316,243 treatment. Single-nuclei transcriptomics identified cell-type-specific re-programming, including altered oxidative phosphorylation and lipid metabolic pathways in adipocytes and increased immune cell representation with sympathetic denervation.
conclusionsTogether, these data demonstrate that sympathetic denervation of scWAT induces coordinated metabolic, lipidomic, and transcriptional changes in the tissue as well as alterations to energy balance. Nerve crosstalk and potential compensation by sensory axons may help explain the findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.